Therapy for vitiligo
AssigneeClinuvel Pharmaceuticals Limited
InventorPhilippe Wolgen
Life of this patent
Estimating the term…
Abstract
The present invention relates to a therapy for vitiligo. In particular the present invention provides a pharmaceutical composition comprising an alpha melanocyte stimulating hormone (alpha-MSH) analog either alone, in combination with narrow band UVB and/or in combination with one or more corticosteroids, immunosuppressants, anti-inflammatory agents and/or photochemotherapeutic agents for the treatment or prevention of vitiligo.
Claims9
A method for treating vitiligo in a subject in need thereof comprising subcutaneously administering to the subject a therapeutically-effective amount of an alpha-MSH analogue, wherein the alpha-MSH analogue is administered in a sustained release composition comprising poly(lactide-co-glycolide), wherein the alpha-MSH analogue is [Nle4, D-Phe7]-alpha-MSH, and further comprising the step of exposing the subject to an effective amount of narrow band ultraviolet B (NB-UVB) light.
Dependencies are inferred from the claim text.